Erschienen in:
01.04.2020 | ASO Author Reflections
ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities
verfasst von:
Joshua C. Leinwand, MD, MSE, Michael D. Kluger, MD, MPH
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) has been transformative in the treatment of peritoneal surface malignancies and is standard of care for diffuse malignant peritoneal mesothelioma (DMPM). In contrast to systemic chemotherapy or resection alone, CRS/HIPEC can address both macroscopic disease surgically as well as microscopic disease with high local concentrations of chemotherapy and also confers the synergistic cytotoxic and pharmacokinetic benefits of hyperthermia. Two large multi-institutional series previously established the safety and efficacy of CRS/HIPEC for DMPM and identified demographic, disease, and treatment factors associated with durable responses in these patients.
1,
2 Our study sought to examine the outcomes of an intent-to-treat series of DMPM patients from a single institution who underwent two planned CRS/HIPEC operations with serial dwell intraperitoneal chemotherapy in the interval between operations.
3 …
